Isotretinoin (When ATH D10BA01)

When ATH:
D10BA01

Characteristic.

Yellow-orange or orange crystalline powder.

Pharmacological action.
Dermatoprotektivnoe.

Application.

Acne.

Contraindications.

Hypersensitivity, of the liver and kidneys, hyperlipidemia, diseases of the rectum, pregnancy (possible teratogenic and embryotoxic manifestations), lactation (at the time of treatment should stop breastfeeding).

Restrictions apply.

Liver disease, kidney, chronic pancreatitis, circulatory failure.

Side effects.

Arthralgia, myalgia, chest pain, rash (эritema, seborrhea, eczema), thinning hair is rarely, intracranial hypertension, mental disorders (depression, tendency to suicide attempts), vasculitis (incl. granulematoz Wegener), dry eyes, decreased night vision, Cataract, conjunctivitis, keratit, enteritis.

Cooperation.

Incompatible with retinoids, providing keratolytic and exfoliative action.

Dosing and Administration.

Inside, the recommended dose is 0.5-2 mg/kg, razdelennaya two parts; It applied for 15-20 weeks. For most patients with sufficient initial dose is 0,5 mg / kg / day, the plight during illness or defeat torso — 2 mg / kg / day. Correction of the dose is dependent on the response to therapy, and / or severity of side effects. If the number of lesions decreased by 70% and more than 15-20 weeks, treatment should be stopped. The second course of treatment is carried out at intervals of not less than 2 months upon confirmation of persistent or recurrent disease progression.

Cautions.

During treatment requires monitoring of blood lipids, Glucose, liver function; Avoid insolation.

Cooperation

Active substanceDescription of interaction
DoxycyclineFMR. Concomitant use is not recommended (reported several cases of brain pseudotumor).
OxytetracyclineFMR: synergism. Co-administration is not recommended (reported cases of brain pseudotumor).
RetinolFMR: synergism. Strengthens (mutually) the risk of toxic effects.
TetracyclineFMR: synergism. Co-administration is not recommended (reported cases of brain pseudotumor).

Back to top button